SEC Form 4 · accession 0001140361-16-047235
Protea Biosciences Group, Inc. · PRGB
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Scott Segal
Director
Period of report
Mar 31, 2015
Accepted (ET)
Jan 8, 2016 · 1:05 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001335103
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Mar 31, 2015 | J | 418,552 | $0.00 | A | 2,375,713 | D | |
| Common StockF2 | Mar 31, 2015 | J | 10,464 | $0.00 | A | 2,386,177 | D | |
| Common Stock | Dec 18, 2015 | A | 80,000 | $0.00 | A | 2,466,177 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Director Stock Option (right to buy)F3 | $0.25 | Dec 18, 2015 | A | 66,667 | A | Dec 1, 2016 | Dec 1, 2025 | Common Stock | 66,667 | 66,667 | D |
Explanation of responses
- F1The Reporting Person held 52,319 shares of the Issuer's Series A Convertible Stock (the "Preferred Shares") with a stated value equal to $2.00 per share (the "Stated Value"). On March 31, 2015, the Preferred Shares automatically converted into shares of the Issuer's common stock (the "Common Stock") determined by dividing the Stated Value by $0.25 per share, resulting in the issuance of 418,552 shares of Common Stock to the Reporting Person.
- F2The Preferred Shares were entitled to receive dividends payable in Common Stock at the rate of 6.0% per annum, which were paid on March 31, 2015.
- F3The option vests 100% on December 1, 2016.